Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular AtrophyGlobeNewsWire • 03/02/23
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)Accesswire • 01/31/23
Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private PlacementGlobeNewsWire • 01/31/23
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq RulesGlobeNewsWire • 01/27/23
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/10/22
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System DisordersGlobeNewsWire • 11/08/22
These Were The Five Best And Worst Performing Healthcare Stocks In September 202224/7 Wall Street • 10/17/22
Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)Accesswire • 10/12/22
Avenue Therapeutics Announces Closing of $12 Million Underwritten Public OfferingGlobeNewsWire • 10/11/22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public OfferingGlobeNewsWire • 10/07/22
Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDAGlobeNewsWire • 09/22/22
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV TramadolGlobeNewsWire • 02/16/22
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)Accesswire • 12/15/21
Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common StockGlobeNewsWire • 12/13/21